Mirum to share Phase 3 AZURE-1 brelovitug topline data in chronic hepatitis delta on Sept. 28 investor call

Bitget2026/09/27 21:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Mirum Pharmaceuticals scheduled an investor call for Sept. 28, 2026 to release topline Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta.
Results have not been presented yet; the event will also include 48-week data from the study’s Phase 2b portion.
The update is expected to clarify whether brelovitug can support a late-stage path toward potential commercialization in hepatitis delta.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609271700BIZWIRE_USPR_____20260927_BW892676) on September 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Mirum to share Phase 3 AZURE-1 brelovitug topline data in chronic hepatitis delta on Sept. 28 investor call

You may also like

Crypto prices